Still, physicians so far are being careful with GLP-1s in oncology, particularly with pancreatic cancer patients or those ...

Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in ...

An HHS spokesperson confirmed Prasad's reappointment as chief medical and scientific officer, one month after his surprising ...

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...

The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug ...

J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that ...

The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market ...

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the ...

Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into ...